BioSpace News Archive

Designed with Exclusive New Features for Bi-Directional Electronic Medical Records Integration Including Auto-Programming and Auto-Documentation

HPPI’s patent portfolio expands with claims covering treatment of both hematologic and non-hematologic cancers with itraconazole, the active ingredient in HPPI’s current and anticipated future product candidates

Ansun is a leading biotechnology company focused on the development of novel broad spectrum anti-viral biologic therapeutics to combat severe viral respiratory tract infections.

OncoQuest Inc. (“OncoQuest”), a privately held, cancer immunotherapy company, today announced the appointment of Dr. Eliel Bayever as Chief Medical Officer.

Augmenix, Inc. is pleased to announce that they will be exhibiting at this year’s American Urological Association meeting in San Francisco, California. Located at Booth 6251 Hall D, the company will be featuring their leading product, SpaceOAR® hydrogel, which is used in patients receiving radiation therapy for prostate cancer.

Gary S. Gillheeney, Sr., President and CEO of Organogenesis Inc., has been appointed to the Massachusetts Biotechnology Council (MassBio) Board of Directors

Coincides with global Boeing well-being initiative Includes $500,000 for veteran recovery and rehabilitation services in Australia, UK and U.S.

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved the subcutaneous (SC) formulation of Actemra® (tocilizumab) for the treatment of active polyarticular juvenile idiopathic arthritis (PJIA) in patients two years of age and older. Actemra can be given alone or in combination with methotrexate (MTX) in patients with PJIA

Data include results from HAVEN 3 study in people with hemophilia A without factor VIII inhibitors and HAVEN 4 study in people with hemophilia A with or without factor VIII inhibitors

Polyneuron Pharmaceuticals AG, a developer of a new class of biodegradable glycopolymer treatments for autoimmune diseases, today announced the closing of a CHF3.1 million financing, following the receipt of a second tranche.